You don't spend shareholder money after your trial failed going to Florence to present failed clinical trial data to a bunch of Europeans who could care less about what you're speaking on. Man up management and cancel the trip...conserve company cash... and not reward yourself and your spouses for failure.
You should spend some time here at home with counsel trying to find out where the info leak was
either at the company, or with someone else, before the SEC does. Now that would be time and money
Shorts probably covered most of theirs this morning. Now we're going to see retail selling after the brief rally this morning and some short positions being put back on for a day trade.
Eat sheet dipsheet..Company just lost alot of $ that they're not going to get from AGN and credibility.
If you're too stupid to figure it out then...like I said...eat sheet dipsheet.
Yes...Some obvously knew the results in advance and the info was leaked to someboody, and why they are going to Florence to reward themselves with a failed trial and present failed trial data is beyond comprehension....
Weiss is the guy who hit the ATM for an average selling cost of $16.66/shr.Think he's very sharp frankly and has no intentions of issuing stock at $7 or in fact until 2018 at the earliest. Think you either read, comprehend and believe what he is saying, or sell the stock and move on.
Congrats on another fine quarter of operations and results. Management has their act together no doubt about it! Long and happy to be part of a company that does what it says it will do! Thanks!
Good idea but legal shorting is not what has driven this stock down. Naked shorting without lawfully borrowing the shares to short IMHO is the cause, and until the SEC comes down on that it will continue
The odds of ZS-9 being approved for "acute" are not a slam dunk either. Remember the FDA rejected RLYP for acute saying our drug "acted within hours, not minutes". Even in a best case scenario for ZS-9 it did not actually reduce K substantially until 2-4 hrs. In an ER situation the drill is basically insulin which acts within minutes. ER docs are not going to take the chance with a patient in potential cardiac arrest and give them ZS9 and see what happens in 2-4 hours! Maybe ZS-9 could be used in some adjunct acute therapy to ER treatment, either in the hospital or outside of it, but certainly as the first line of ER treatment.
ZS9 has shown a high incidence of edema. . If the year follow on study was actually released in total, some docs estimated it would have been as high as 15%. As for HTN? Who knows since the measuring bar for HTN in the ZS9 year follow on study was 180/110, and we've never seen those results either. The bar for ZS9 in HTN basically means the person should be in the ER getting emergency treatment for HTN. That is how absurd their year follow on trial design was.
If one has HTN.. or.a history of edema.... or is being treated for CHF, do. you think a doc is going to prescribe for them something that has a Na exchange bias? No way. Why would they when Velt is already out there and is CA based?
The only way ZS9 gets approved without a box warning for chronic use is if the game is rigged and
AZN truly does own the FDA. If you think that is not possible so be it. We'll see shortly won't we?
Only exception I can take with your post is "market is big enough for both".
Right now the entire market generated sales of approx 600k for an entire quarter.
Don't think that ramp is big enough for one let alone two... The potential market is just that...potential. Last I saw my bank wasn't accepting potential checks for deposit.
Nice to hear from you again AK. Again...Congrats on how you played ZSPH. I was wrong and you were right...What can I say? LOL!